Microsomal prostaglandin e synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/Β-catenin signaling axis

Oncogene

Volumn 31, Issue 7, 2012, Pages 842-857

  Lu, D ^a,b   Han, C ^a   Wu, T ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TONGJI UNIVERSITY   (China)

Author keywords

b catenin; early growth response 1; hepatocellular carcinoma; liver; microsomal prostaglandin E synthase 1

Indexed keywords

BETA CATENIN; EARLY GROWTH RESPONSE FACTOR 1; LYMPHOID ENHANCER FACTOR 1; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; SMALL INTERFERING RNA; T CELL FACTOR 4; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CARCINOMA CELL; CELL MIGRATION; CLONOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; DNA FLANKING REGION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN PROTEIN INTERACTION; TUMOR PROMOTION;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DINOPROSTONE; EARLY GROWTH RESPONSE PROTEIN 1; HUMANS; IMMUNOPRECIPITATION; INTRAMOLECULAR OXIDOREDUCTASES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; PROTEIN BINDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857120005     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.287     Document Type: Article

References (67)

1. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG et al. (2001). Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7: 1410-1418. (Pubitemid 32717225)
2. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A et al. (2006). A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682. (Pubitemid 44958508)
3. Bijur GN, Jope RS. (2001). Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276: 37436-37442.
4. Henderson BR. (2000). Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2: 653-660.
5. Branda M, Wands JR. (2006). Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 43: 891-902. (Pubitemid 43724611)
6. Caspi M, Zilberberg A, Eldar-Finkelman H, Rosin-Arbesfeld R. (2008). Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. Oncogene 27: 3546-3555. (Pubitemid 351793805)
7. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510. (Pubitemid 41746348)
8. Cheng AS, Chan HL, To KF, Leung WK, Chan KK, Liew CT et al. (2004). Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virusassociated hepatocellular carcinoma. Int J Oncol 24: 853-860.
9. Clevers H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
10. Couzin J. (2004). Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 306: 1673-1675.
11. Danesch U, Weber PC, Sellmayer A. (1994). Arachidonic acid increases c-fos and Egr-1 mRNA in 3T3 fibroblasts by formation of prostaglandin E2 and activation of protein kinase C. J Biol Chem 269: 27258-27263. (Pubitemid 24346543)
12. Diehl JA, Cheng M, Roussel MF, Sherr CJ. (1998). Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511. (Pubitemid 28553242)
13. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. (2005). Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis 26: 1503-1512. (Pubitemid 41236043)
14. El-Serag HB, Mason AC. (1999). Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750. (Pubitemid 29114292)
15. El-Serag HB. (2004). Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27-S34. (Pubitemid 39423367)
16. Farazi PA, DePinho RA. (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687. (Pubitemid 44286000)
17. Giles RH, van Es JH, Clevers H. (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24. (Pubitemid 36627817)
18. Gitenay DBV. (2009). Is EGR1 a potential target for prostate cancer therapy? Future Oncol 5: 993-1003.
19. Gordon MD, Nusse R. (2006). Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281: 22429-22433.
20. Grosser T, Fries S, FitzGerald GA. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15. (Pubitemid 43121782)
21. Han C, Michalopoulos GK, Wu T. (2006). Prostaglandin E(2) receptor EP(1) transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207: 261-270.
22. Hanaka H, Pawelzik SC, Johnsen JI, Rakonjac M, Terawaki K, Rasmuson A et al. (2009). Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci USA 106: 18757-18762.
23. Hoppler S, Kavanagh CL. (2007). Wnt signalling: variety at the core. J Cell Sci 120: 385-393. (Pubitemid 46332502)
24. Itoh K, Brott BK, Bae GU, Ratcliffe MJ, Sokol SY. (2005). Nuclear localization is required for dishevelled function in Wnt/beta-catenin signaling. J Biol 4: 3.
25. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. (1999). Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96: 7220-7225. (Pubitemid 29299642)
26. Kamei D, Murakami M, Sasaki Y, Nakatani Y, Majima M, Ishikawa Y et al. (2010). Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. Biochem J 425: 361-371.
27. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL. (2007). Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 46: 108-125. (Pubitemid 46661865)
28. Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ. (2007). Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem 282: 5356-5366. (Pubitemid 47093760)
29. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K et al. (1999). Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29: 688-696. (Pubitemid 29109581)
30. Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J et al. (1999). Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 5: 4005-4012. (Pubitemid 30013777)
31. Lee KH KJ. (2009). Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells. Clin Exp Metastasis 26: 685-692.
32. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. (2003). Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxibinduced apoptosis. Hepatology 38: 756-768. (Pubitemid 37052162)
33. Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu T. (2008). Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res 68: 553-560. (Pubitemid 351380084)
34. Lim K, Han C, Dai Y, Shen M, Wu T. (2009). Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 8: 3046-3055.
35. Llovet JM, Bruix J. (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
36. Ma J, Ren Z, Ma Y, Xu L, Zhao Y, Zheng C et al. (2009). Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NFkappaB synergy. J Biol Chem 284: 34600-34606.
37. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A et al. (2004). Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 127: 1110-1122. (Pubitemid 39345880)
38. Monga SP. (2006). Hepatic adenomas: presumed innocent until proven to be beta-catenin mutated. Hepatology 43: 401-404.
39. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. (2004).WNT and betacatenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701. (Pubitemid 39150127)
40. Moon Y, Lee M, Yang H. (2007). Involvement of early growth response gene 1 in the modulation of microsomal prostaglandin E synthase 1 by epigallocatechin gallate in A549 human pulmonary epithelial cells. Biochem Pharmacol 73: 125-135. (Pubitemid 44868978)
41. Morisco CSK, Hardt SE, Lee Y, Vatner SF, Sadoshima J. (2001). Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem 276: 28586-28597.
42. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F et al. (2000). Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275: 32783-32792.
43. Murakami M, Kudo I. (2006). Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr Pharm Des 12: 943-954.
44. Ngiam N, Peltekova V, Engelberts D, Otulakowski G, Post M, Kavanagh BP. (2010). Early growth response-1 worsens ventilatorinduced lung injury by up-regulating prostanoid synthesis. Am J Respir Crit Care Med 181: 947-956.
45. Parra E, Ortega A, Saenz L. (2009). Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3. Oncol Rep 22: 1513-1518.
46. Philipp-Staheli J, Kim KH, Payne SR, Gurley KE, Liggitt D, Longton G et al. (2002). Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell 1: 355-368. (Pubitemid 41039137)
47. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H et al. (2001). Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C viruspositive cases. Clin Cancer Res 7: 1325-1332. (Pubitemid 32708688)
48. Saegusa M, Hashimura M, Kuwata T, Hamano M, Okayasu I. (2004). Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol 164: 1739-1749. (Pubitemid 38529776)
49. Saegusa M, Hashimura M, Kuwata T, Hamano M, Watanabe J, Kawaguchi M et al. (2008). Transcription factor Egr1 acts as an upstream regulator of beta-catenin signalling through up-regulation of TCF4 and p300 expression during trans-differentiation of endometrial carcinoma cells. J Pathol 216: 521-532.
50. Samuelsson B, Morgenstern R, Jakobsson PJ. (2007). Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224. (Pubitemid 47481434)
51. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T et al. (2000). AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24: 245-250. (Pubitemid 30132191)
52. Shao J, Jung C, Liu C, Sheng H. (2005). Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 280: 26565-26572. (Pubitemid 41022254)
53. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y et al. (1999). Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46: 407-412. (Pubitemid 29154786)
54. Smith WL, DeWitt DL, Garavito RM. (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182.
55. Smith WL, Langenbach R. (2001). Why there are two cyclooxygenase isozymes. J Clin Invest 107: 1491-1495. (Pubitemid 32574631)
56. Stichtenoth DO, Thorén S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. (2001). Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 167: 469-474. (Pubitemid 32567813)
57. Subbaramaiah K, Yoshimatsu K, Scherl E, Das KM, Glazier KD, Golijanin D et al. (2004). Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem 279: 12647-12658. (Pubitemid 38445836)
58. Takii Y, Abiru S, Fujioka H, Nakamura M, Komori A, Ito M et al. (2007). Expression of microsomal prostaglandin E synthase-1 in human hepatocelluar carcinoma. Liver Int 27: 989-996. (Pubitemid 47261954)
59. Tetsu O, McCormick F. (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426. (Pubitemid 29180374)
60. Thiel G, Mayer SI, Muller I, Stefano L, Rossler OG. (2010). Egr-1-A Ca(2+)-regulated transcription factor. Cell Calcium 47: 397-403.
61. Thompson MD, Monga SP. (2007). WNT/beta-catenin signaling in liver health and disease. Hepatology 45: 1298-1305. (Pubitemid 46775794)
62. Thoren S, Weinander R, Saha S, Jegerschold C, Pettersson PL, Samuelsson B et al. (2003). Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 278: 22199-22209. (Pubitemid 36830265)
63. Vanchieri C. (2004). Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 96: 1734-1735. (Pubitemid 39654560)
64. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T et al. (2001). The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 3: 1124-1128. (Pubitemid 33130464)
65. Wu T. (2006). Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32: 28-44. (Pubitemid 43159775)
66. Yu J, Zhang SS, Saito K, Williams S, Arimura Y, Ma Y et al. (2009). PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J 28: 21-33.
67. Zucman-Rossi J, Jeannot E, Van Nhieu JT, Scoazec JY, Guettier C, Rebouissou S et al. (2006). Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43: 515-524.